Autoantigens Plus Interleukin-10 Suppress Diabetes Autoimmunity

被引:17
|
作者
Denes, Bela [1 ,2 ]
Fodor, Istvan [1 ]
Langridge, William H. R. [1 ]
机构
[1] Loma Linda Univ, Ctr Hlth Dispar & Mol Med, Dept Biochem & Microbiol, Loma Linda, CA 92350 USA
[2] Cent Vet Inst, Dept Immunol, Budapest, Hungary
基金
美国国家卫生研究院;
关键词
TOXIN B-SUBUNIT; GLUTAMIC-ACID DECARBOXYLASE; ANTIGEN-PRESENTING CELLS; REGULATORY T-CELLS; CHOLERA-TOXIN; NOD MICE; VACCINIA VIRUS; GENE-TRANSFER; MUCOSAL IMMUNITY; TRANSGENIC EXPRESSION;
D O I
10.1089/dia.2009.0116
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recombinant vaccinia virus (rVV) strains expressing the immunomodulatory cholera toxin B subunit (CTB) fused to the autoantigen glutamic acid decarboxylase (GAD) or the immunosuppressive cytokine interleukin-10 (IL-10) were independently able to generate only low levels of immune suppression of type 1 diabetes mellitus (T1DM). Here we suggest that a vaccinia virus (VV)-mediated combination of CTB::GAD fusion and IL-10 proteins promises a effective and durable immunotherapeutic strategy for T1DM. Methods: To explore this hypothesis, a CTB::GAD fusion gene was co-delivered with a gene encoding IL-10 by rVV infection (rVV-CTB::GAD+rVV-IL10) into 5-7-week-old non-obese diabetic (NOD) mice. The mice were assessed for vaccine protection against development of hyperglycemia from 12 to 64 weeks of age by assessment of pancreatic inflammation (insulitis) and splenocyte-secreted interferon-gamma and IL-10 cytokine levels. Results: By 36 weeks of age, from 54% to 80% of the mice in the negative control animal groups (either mock-infected or inoculated with unrelated plasmid or VV) had developed hyperglycemia. Similarly, no statistically significant improvement in protection against diabetes onset was achieved by inoculation with VV expressing CTB::GAD or IL-10 independently. Surprisingly, only 20% of mice co-inoculated with rVV-CTB::GAD+rVV-IL10 developed hyperglycemia by 28 weeks of age. Other treatment groups developed hyperglycemia by 32-36 weeks. After 36 weeks, diabetes incidence no longer increased in any groups until the end of experiment at 64 weeks of age. Histological analysis of pancreatic tissues of hyperglycemic mice revealed high levels of intra-islet insulitis. Analysis of insulitis at termination of the experiment showed that euglycemic mice co-inoculated with VV expressing CTB::GAD and IL-10 had more effectively reduced inflammation in comparison with the other groups. Conclusions: A combinatorial vaccination strategy based on VV co-delivery of genes encoding the immuno-enhanced autoantigen CTB::GAD and the anti-inflammatory cytokine IL-10 can maintain effective and durable euglycemia and immunological homeostasis in NOD mice with prediabetes.
引用
收藏
页码:649 / 661
页数:13
相关论文
共 50 条
  • [32] Interleukin-10 plasmid construction and delivery for the prevention of type 1 diabetes
    Lee, Minhyung
    Park, Hyewon
    Kim, Sungwan
    Park, Yongsoo
    DIABETES, 2006, 55 : A281 - A281
  • [33] Complete Freunds Adjuvant can protect from Retinal Autoimmunity by an Interleukin-10 dependent mechanism
    Grajewski, Rafael S.
    Scholz, Rebecca
    Hos, Deniz
    Cursiefen, Claus
    Heindl, Ludwig M.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [34] Treatment of psoriasis with interleukin-10
    Reich, K
    Brück, M
    Gräfe, A
    Vente, C
    Neumann, C
    Garbe, C
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 111 (06) : 1235 - 1236
  • [35] PROPERTIES AND FUNCTIONS OF INTERLEUKIN-10
    MOSMANN, TR
    ADVANCES IN IMMUNOLOGY, VOLUME 56, 1994, 56 : 1 - 26
  • [36] Interleukin-10 and coronary disease
    Fernández, RP
    Kaski, JC
    REVISTA ESPANOLA DE CARDIOLOGIA, 2002, 55 (07): : 738 - 750
  • [37] Interleukin-10 in der Dermatologie
    Khusru Asadullah
    Wolf-Dietrich Döcke
    Robert Sabat
    Merle Ebeling
    Hans-Dieter Volk
    Wolfram Sterry
    Der Hautarzt, 1999, 50 : 12 - 19
  • [38] Clinical development of interleukin-10
    Lebeaut, A
    Garaud, JJ
    EUROPEAN CYTOKINE NETWORK, 1997, 8 (03) : 303 - 304
  • [39] The interleukin-10 family of cytokines
    Fickenscher, H
    Hör, S
    Küpers, H
    Knappe, A
    Wittmann, S
    Sticht, H
    TRENDS IN IMMUNOLOGY, 2002, 23 (02) : 89 - 96
  • [40] Interleukin-10 and liver diseases
    Le Moine, O
    Louis, H
    Sermon, F
    Goldman, M
    Devière, J
    ACTA GASTRO-ENTEROLOGICA BELGICA, 1999, 62 (01) : 1 - 8